Live from the NIH registry
Studies recruiting near Salinas right now
Top 25 of 46 recruiting studies, sorted by proximity — each links to its official registry page
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Lymphoma, Non-Hodgkin, Multiple Myeloma
Phase 2
Interventional 4,200 participants sought
Sutter Palo Alto Medical Foundation: Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: American Society of Clinical Oncology
Phase II: Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical Settings
Anxiety, Mood Disorders
N/A
Interventional 156 participants sought
Ohana Center for Child and Adolescent Behavioral Health — Monterey, California (15.8 mi)
· Sponsor: Stanford University
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma
Phase 2
Interventional 152 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 3
Interventional 360 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: National Cancer Institute (NCI)
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Breast Cancer, Early Breast Cancer
Phase 3
Interventional 5,500 participants sought
Research Site — Monterey, California (15.8 mi)
· Sponsor: AstraZeneca
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
COPD (Chronic Obstructive Pulmonary Disease)
Phase 3
Interventional 5,000 participants sought
Research Site — Castroville, California (8.8 mi)
· Sponsor: AstraZeneca
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Phase 3
Interventional 880 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: NRG Oncology
An External Control Arm Study in Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
N/A
Observational 650 participants sought
Pacific Cancer Care — Monterey, California (15.8 mi)
· Sponsor: N-Power Medicine
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Stage I Breast Cancer
Phase 3
Interventional 1,670 participants sought
Dominican Santa Cruz Hospital — Santa Cruz, California (29.6 mi)
· Sponsor: NRG Oncology
Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA)
Middle Schools, School Exclusion
N/A
Interventional 5,076 participants sought
Soquel Union Elementary School District — Capitola, California (26.6 mi)
· Sponsor: University of Oregon
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Salinas Valley Memorial — Salinas, California (1.5 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Renal Pelvis and Ureter Urothelial Carcinoma
Phase 2, Phase 3
Interventional 131 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: National Cancer Institute (NCI)
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Diabetic Kidney Disease (DKD)
Phase 2
Interventional 195 participants sought
Central Coast Nephrology — Salinas, California (1.5 mi)
· Sponsor: Regeneron Pharmaceuticals
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial Meningioma, Recurrent Meningioma
Phase 2
Interventional 124 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC)
Phase 3
Interventional 1,040 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
N/A
Observational 130 participants sought
Pacific Cancer Care — Monterey, California (15.8 mi)
· Sponsor: N-Power Medicine
Product Surveillance Registry
Cardiac Rhythm Disorders, Urological Disorders
N/A
Observational 100,000 participants sought
Research site — Salinas, California (1.5 mi)
· Sponsor: Medtronic
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Lumbar Spinal Stenosis
N/A
Observational 8,000 participants sought
Salinas Surgery Center — Salinas, California (1.5 mi)
· Sponsor: Stryker Instruments
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Cardiovascular Disease
Phase 3
Interventional 15,100 participants sought
Research Site — Castroville, California (8.8 mi)
· Sponsor: AstraZeneca
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3
Interventional 3,680 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: National Cancer Institute (NCI)
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
End Stage Kidney Disease
Phase 2, Phase 3
Interventional 3,110 participants sought
Central Coast Nephrology Medical Corp — Salinas, California (1.5 mi)
· Sponsor: CSL Behring
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Phase 3
Interventional 1,295 participants sought
Salinas Valley Memorial — Salinas, California (1.5 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 2
Interventional 56 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: SWOG Cancer Research Network
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
Phase 3
Interventional 3,960 participants sought
Salinas Valley Memorial — Salinas, California (1.5 mi)
· Sponsor: NRG Oncology
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Arrhythmia, Bradycardia
N/A
Observational 20,000 participants sought
Research site — Salinas, California (1.5 mi)
· Sponsor: Medtronic